Opinion
Video
Cara Chang, PharmD, BCOP, examines the prevalence of EGFR positivity, provides an overview of clinically relevant EGFR mutations, and discusses therapeutic options for EGFR-positive mutations.
FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer